#Sustainability #Sweden #Lund #Hansa Biopharma #IDEFIRIX

Hansa Biopharma's 2024 Annual and Sustainability Reports

Hansa Biopharma AB, a prominent player in the biopharmaceutical industry, has officially released its Annual and Sustainability Reports for the year 2024. This pivotal moment was marked by a significant address from Peter Nicklin, Chair of the Board, who praised the company’s achievements and its steadfast commitment to advancing innovative therapies.

Key Highlights from 2024

The year 2024 proved to be a momentous one for Hansa Biopharma, characterized by the impressive 83% growth in sales of their flagship product, IDEFIRIX® (imlifidase). This drug, effectively used in Europe for desensitizing kidney transplant patients, has seen record sales across all 18 markets where it's available, including crucial regions like France, Germany, Italy, Spain, and the UK.

Søren Tulstrup, President and CEO, emphasized the importance of 2024 as a year of momentum that strategically places Hansa for future successes in Autoimmune, Gene Therapy, and Transplantation areas. The company is looking forward to critical milestones in 2025, including a planned submission for a Biologics License Application (BLA) to the U.S. FDA for kidney transplantation.

Clinical Advancements and Research

Hansa Biopharma's dedication to research is underscored by several concrete advancements. In 2024, the company completed the pivot to commercialization in the U.S. with the pivotal Phase 3 trial for imlifidase, ensuring comprehensive data collection and evaluation processes for its effectiveness in highly sensitized kidney transplant patients. The expected data readout will be crucial as the company engages with regulatory bodies.

Hansa also shared positive results from its recent clinical trials, including HNSA-5487's performance in human trials that showcased its potential in reducing IgG levels effectively, indicating promising applications in treating neuro-autoimmune diseases like myasthenia gravis. Continuing advancements in Autoimmune areas, they completed enrollment for critical trials while also launching innovative gene therapy collaborations to further explore treatment avenues.

Commitment to Sustainability

Beyond its commercial successes, Hansa Biopharma's Sustainability Report outlines the company's actions and strategies aimed at addressing significant medical needs. The report emphasizes Hansa's commitment to ethical operations and a transparent business model, embodying the values of diversity and inclusivity among its workforce. The company believes these elements are crucial for long-term success and innovation.

Hansa also engaged in a Double Materiality Assessment which highlighted the company's impacts and opportunities regarding its sustainability strategy. Recognizing the evolving landscape of healthcare and environmental responsibility, Hansa is well-positioned to navigate challenges while delivering meaningful solutions.

Employee engagement remains a cornerstone of Hansa's culture. The Great Place to Work® certification received for the fifth consecutive year, with a remarkable 95% survey response rate, signifies the company's devotion to fostering a supportive and positive work environment.

Conclusion

As we look forward to 2025, Hansa Biopharma is not only enhancing its portfolio with groundbreaking therapies but also ensuring that its growth is anchored in sustainability principles and employee well-being. The commitment to innovation, customer-first approaches, and social responsibility will undoubtedly define Hansa's path in the biopharmaceutical landscape for years to come. To read more, you can access the full Annual and Sustainability Reports on Hansa's official website.